Addressing the challenges inherent in interpreting IGRA results,particularly in cases of IGRA reversion, was highlighted as a majorneed by the panel. Currently, it cannot be determined with confi-dence whether a person who demonstrates a transiently positiveIGRA result was infected with Mtb and then cleared it, or whethersuch a result represents vagaries in the assay. Clarifying thissituation would represent an important contribution to effortsattempting to assess TB vaccines for their ability to prevent sus-tained Mtb infection.